Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

November 22, 2019

Complete Revascularization Benefits May Be Due to Stenting Vulnerable Plaques

News Conference News AHA 2019

Complete Revascularization Benefits May Be Due to Stenting Vulnerable Plaques

November 21, 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

News Conference News AHA 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

November 20, 2019

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

News Conference News AHA 2019

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

November 19, 2019

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

News Conference News AHA 2019

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

Yael L. Maxwell

November 19, 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

November 18, 2019

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

News Conference News AHA 2019

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

November 18, 2019

TAVR Valve Face-off: Two French Observational Studies Suggest Inherent Differences

News Conference News AHA 2019

TAVR Valve Face-off: Two French Observational Studies Suggest Inherent Differences

Yael L. Maxwell

November 18, 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

November 17, 2019

No Benefit of Colchicine in All-Comers PCI

News Conference News AHA 2019

No Benefit of Colchicine in All-Comers PCI

November 17, 2019

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

News Conference News AHA 2019

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

November 17, 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

News Conference News AHA 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Yael L. Maxwell

November 17, 2019

Early Surgery Beats a Conservative Approach in Asymptomatic AS: RECOVERY

News Conference News AHA 2019

Early Surgery Beats a Conservative Approach in Asymptomatic AS: RECOVERY

Yael L. Maxwell

November 16, 2019

ISCHEMIA-CKD: Routine Invasive Approach No Help in CKD Patients With Stable CAD

News Conference News AHA 2019

ISCHEMIA-CKD: Routine Invasive Approach No Help in CKD Patients With Stable CAD

November 16, 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

News Conference News AHA 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Yael L. Maxwell

November 16, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

November 16, 2019

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

News Conference News AHA 2019

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

Michael O'Riordan

November 14, 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

News Conference News AHA 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Michael O'Riordan

November 13, 2019

News Opinion Off Script AHA 2019

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

Ajay Kirtane, MD, SM

November 12, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.